In its most recent SEC filing for the third quarter, Virginia Retirement Systems et al. disclosed a 12.3% increase in its Johnson & Johnson holdings. The fund acquired an additional 127,100 shares, bringing its total position to 1,158,903 shares, which represented 1.4% of its portfolio and ranked as its ninth largest holding. By quarter end, the value of this stake stood at $214.9 million, underscoring continued institutional confidence in JNJ’s diversified healthcare operations.

Johnson & Johnson’s board declared a first-quarter cash dividend of $1.30 per share, payable on March 10, 2026, to shareholders of record as of February 24, 2026. This quarterly payout translates into an annualized dividend of $5.20 per share and reflects a payout ratio of approximately 50.2%. The stable yield supports the company’s status as a Dividend King, marking 63 consecutive years of annual increases and appealing to income-focused investors seeking consistent distributions.

For the third quarter, JNJ reported revenue of $24.02 billion and earnings per share of $2.26, translating into a net margin of 27.3% and a return on equity of 32.7%. Through three quarters, the company has generated roughly $14 billion in free cash flow while investing $10.4 billion in research and development. These figures illustrate JNJ’s capacity to fund innovation—such as its recent $3.1 billion acquisition of Halda Therapeutics—while maintaining disciplined capital allocation and shareholder returns.

Following recent research notes, four equities analysts have issued Strong Buy opinions, fourteen have recommended Buy and nine have advised Hold, resulting in an average consensus rating of Moderate Buy. Notable revisions include target price increases by Bank of America from $204 to $220 and by Barclays from $197 to $217. MarketBeat data indicates an average price target of $211.25, reflecting analyst confidence in JNJ’s growth prospects across pharmaceuticals, medical devices and consumer health segments.